Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will now oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs, including translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical juncture for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. According to the company, Fang has played a key role in advancing its clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones. The full press release is available at https://ibn.fm/c9jdt.
Headquartered in Malvern, Pennsylvania, Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Fang’s appointment underscores the company’s focus on executing its clinical strategy and preparing for regulatory interactions. As Annovis nears a pivotal data readout, the leadership change signals organizational readiness for the next phase of development. Investors and stakeholders can follow updates on the company’s newsroom at https://ibn.fm/ANVS.
